Rapport Therapeutics, Inc.
RAPPHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Headquartered within the healthcare sector, Rapport Therapeutics, Inc. focuses on Biotechnology services and products. Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering. The company carries a $1.89B market cap, placing it firmly in the small-cap category. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Market Cap
$1.89B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.84
EPS (TTM)
$-2.60
EPS (Fwd)
$-4.47
ROE
-28.3%
ROA
-19.1%
Cash
$476.8M
Total Debt
$10.8M
Free CF
-$49.4M
52W Change
377.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $476.8M in cash comfortably exceeding the $10.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$49.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -28.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing RAPP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.